Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This study is ongoing, but not recruiting participants.
Dana-Farber Cancer Institute
First Posted: June 20, 2012
Last Update Posted: March 23, 2017
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute